×
About 720 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  252 results

Cytopathological characteristics of angioimmunoblastic T-cell lymphoma diagnosed by fin...
https://doi.org/10.1111/cyt.13099
Cytopathology : Official Journal of the British Society F... Fei M, Ye Q et. al.

Jan 18th, 2022 - To analyse the cytopathological features of fine-needle aspiration (FNA) in angioimmunoblastic T-cell lymphoma (AITL) diagnostics. FNA lymph node biopsy samples from 12 patients with AITL were collected at a single centre between January 2014 and ...

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

Jan 6th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymph...
https://clinicaltrials.gov/ct2/show/NCT04251065

Jan 3rd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Cutaneous Involvement of Angioimmunoblastic T-Cell Lymphoma Masquerading as B-Cell Reac...
https://doi.org/10.1097/DAD.0000000000002110
The American Journal of Dermatopathology; Pesqué D, Marcantonio O et. al.

Dec 31st, 2021 - A 59-year-old woman presented with a persistent eruption manifested as multiple agminated miliary facial papules. Histopathological examination showed prominent nodular dermal lymphoid infiltrates with hyperplastic follicles that were initially in...

Utility of a new notation to visualize flow cytometry analysis results: first prelimina...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690966
BMC Cancer; Fujishima F, Fukuhara N et. al.

Dec 22nd, 2021 - It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining f...

see more →

Clinicaltrials.gov  12 results

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

Jan 6th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymph...
https://clinicaltrials.gov/ct2/show/NCT04251065

Jan 3rd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Study of Lacutamab in Peripheral T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04984837

Dec 7th, 2021 - This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lympho...

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms
https://clinicaltrials.gov/ct2/show/NCT03493451

Jul 8th, 2021 - This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There will be two...

Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02561273

Jun 18th, 2021 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...

see more →

News  24 results

Duvelisib plus Romidepsin Displays Activity in R/R PTCL
https://www.onclive.com/view/duvelisib-plus-romidepsin-displays-activity-in-r-r-ptcl

Dec 13th, 2021 - The combination of duvelisib (Copiktra) plus romidepsin (Istodax; DR) was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma (PTCL), according to final results from the dose expansion stage of a phase 1 trial (NCT027836...

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL
https://www.onclive.com/view/remaining-echelon-2-questions-spark-novel-research-efforts-in-ptcl

Feb 17th, 2021 - Questions from the phase 3 ECHELON-2 trial (NCT01777152), which led to the 2018 FDA approval of brentuximab vedotin (Adcetris) plus chemotherapy for patients with CD30-expressing peripheral T-cell lymphoma (PTCL), have given way to additional rese...

Anti-ICOS Antibody MEDI-570 Elicits Durable Responses in Relapsed/Refractory T-cell Lymphomas
https://www.onclive.com/view/anti-icos-antibody-medi-570-elicits-durable-responses-in-relapsed-refractory-t-cell-lymphomas

Dec 20th, 2020 - The anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma (AIT...

Reddy Reviews Paradigm Shifts in CD30-Positive PTCL, Next Steps for Research
https://www.onclive.com/view/reddy-reviews-paradigm-shifts-in-cd30-positive-ptcl-next-steps-for-research

Nov 16th, 2020 - The emergence of brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, and prednisone (CHP) in the treatment armamentarium for advanced peripheral T-cell lymphoma (PTCL) led to a shift in the paradigm for patients with CD30 positivity...

Brentuximab Vedotin Shows Broadening Benefit Across Lymphoma Subtypes
https://www.onclive.com/view/brentuximab-vedotin-shows-broadening-benefit-across-lymphoma-subtypes

Sep 14th, 2020 - The emergence of the antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) has had a positive impact on improving overall survival (OS) and progression-free survival (PFS) for patients with T-cell lymphomas and classical Hodgkin lymphoma (c...

see more →